Introduction: Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor tyrosine kinase gene (ALK) testing. Next-generation sequencing (NGS) reveals more actionable genomic alterations than do standard diagnostic methods. Data on the influence of hybrid capture (HC)-based NGS on treatment are limited, and we investigated its impact on treatment decisions and clinical outcomes.
Introduction
NSCLC tumors are highly genetically diverse and present a treatment challenge. 1 Until a decade ago, systemic treatment for advanced lung cancer focused primarily on platinum-based doublets. 2 In 2002, the concept of "oncogene addiction" was introduced by Weinstein et al., 3 and since then important advances in understanding lung cancer cellular signal pathways have been made, leading to the development of multiple targeted drugs.
The new treatment paradigm in lung cancer focuses on personalizing treatment on the basis of tumor molecular properties, specifically, on targeting driver genomic alterations (GAs). [4] [5] [6] [7] [8] [9] Tumor genotyping allows detection of oncogenic drivers in approximately 60% of patients with lung adenocarcinoma, and using the appropriate targeted treatment has a significant impact on survival. [10] [11] [12] The most frequently altered genes are KRAS, EGFR, and anaplastic lymphoma receptor tyrosine kinase gene (ALK), which are detected in 15% to 25%, 10% to 35%, and 3% to 7% of patients, respectively. [13] [14] [15] [16] At present, the KRAS driver cannot be effectively targeted; thus, the current treatment strategy focuses on targeting GAs in the EGFR and ALK genes. However, current typical technologies for identifying GAs (i.e., polymerase chain reaction [PCR] , immunohistochemistry, and fluorescence in situ hybridization [FISH] ) cannot identify all druggable alterations in EGFR exons and/or introns or variants of ALK rearrangement. 5, 7, [10] [11] [12] Other targets that are not routinely tested in lung adenocarcinoma include ret proto-oncogine (RET) (1%), ROS1 (1%), Mesenchymalepithelial transition factor (MET) receptor tyrosine kinase gene (2%), and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (2%). 13 Massive parallel sequencing (i.e., next-generation sequencing [NGS] ), is a new platform that allows detection of numerous GAs in tens to hundreds of genes simultaneously, as well as detection of rare somatic mutations. One NGS approach uses PCR amplification of candidate regions followed by NGS (amplicon sequencing) and offers sequencing of a narrow gene spectrum, focusing on point mutations in several hotspot regions. Other, more comprehensive methods such as hybrid capture (HC)-based NGS offer broad gene sequencing and provide extensive genetic information regarding the broad aberration repertoire, including information on exon and intron mutations, gene rearrangements, amplifications, etc.
Clinical utilization of NGS began in 2011. Since then, NGS assays have improved considerably, with respect to the bioinformatics involved, as well as with respect to translational/clinical implementation. 17 A study from 2013 investigated the genetic repertoire of 2221 clinical specimens by using HC-based NGS and detected actionable GAs in 76% of tumors, which is three times the number detected by traditional diagnostic tests. 18 NGS is also applicable to liquid biopsies, a novel strategy for cancer diagnosis. Since circulating tumor cell-free DNA (cfDNA) was discovered by Stroun et al. in 1987, 19 numerous technologies have been developed to detect and use these genetic materials as an alternative to invasive tissue biopsy. [20] [21] [22] Notably, cfDNA may mirror in real time the spatial genomic repertoire of the tumor in contrast to pathologic specimens that reflect the genomic status at the time of biopsy.
Although HC-based NGS allows elaborate molecular characterization of the tumor, many of the GAs are not druggable (i.e., without an associated therapy that is approved and commercially available). The cost of HC-based NGS, as well as treatment reimbursement issues, should be considered. Therefore, the role of HC-based NGS in disease management is unclear. Here, we assessed the contribution of HC-based NGS to clinical decision making and clinical outcomes in real-life clinical practice while also considering other diagnostic tests carried out according to physicians' decisions.
Materials and Methods

Patients
This retrospective cohort study included 101 sequential patients with advanced lung cancer who were treated at the Davidoff Cancer Center at Rabin Medical Center (Petah Tikva, Israel) between November 2011 and October 2015 and underwent HC-based NGS with broad gene panels. HC-based NGS was performed upon the recommendation of the treating physician, mostly on the basis of young age and smoking history. The results of standard molecular testing for EGFR mutations and ALK rearrangements (using validated and approved diagnostic kits) were negative before HC-based NGS in 80.2% (81 of 101) and 70.3% (71 of 101) of the patients, respectively. Upfront HC-based NGS was performed on 15 patients because of very little biopsy material. Bloodbased cfDNA analysis served as a salvage method for gene analysis in cases of tissue exhaustion. The study was approved by the ethical committee of Rabin Medical Center (approval no. 0391-14 RMC). The clinicopathologic data were collected from patients' medical and electronic charts.
HC-Based NGS Cancer Gene Tests
HC-based NGS was performed off-site on tumor samples with FoundationOne (Foundation Medicine, Inc., Cambridge, MA) 18 or on blood samples using a liquid biopsy approach with Guardant360 (Guardant Health Inc., Redwood City, CA) if the tissue sample had been exhausted. 20 (For extended information on these HC-based NGS technologies, see the Supplementary Data). Both assays were paid either out of pocket or by private insurance coverage. An effort was made to financially assist patients who could not fund tests.
Standard Molecular Pathology Tests
EGFR mutations were assessed with real-time PCR or narrow-spectrum NGS assays (amplicon-based hotspot NGS). ALK rearrangements were assessed with immunohistochemistry and/or FISH (for extended information on these methods, see the Supplementary Data).
Gene Analysis
This study focused on GAs with potential clinical relevance. Initial analysis (level 1) included GAs associated with U.S. Food and Drug Administration-approved anticancer therapies (including off-label drugs) for all cancer types. A subsequent analysis (level 2) included GAs with appropriate evidence-based targeted agents with antidriver activity in lung cancer, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. 23 GAs associated with investigational treatments were not included in the current analysis, although one patient went on to participate in a driver-based clinical trial.
Results
Patient Characteristics
The analysis included 101 patients with advanced lung cancer. Patient characteristics are summarized in Table 1 . Patients' median age at diagnosis was 63 years (range 20-84), 94% of patients had their lung cancer diagnosed at stage III to IV, 53% were women, 45% were never-smokers, and 85% had adenocarcinoma. Routine molecular analysis for EGFR mutations and ALK rearrangement was performed in 86 and 72 patients, respectively. In general, no alterations were detected except in five cases of inconclusive EGFR alterations and one case of inconclusive ALK rearrangement. In 15 patients (14.9%), HC-based NGS testing was performed before routine molecular testing. In 52 patients (51.5%), HC-based NGS was performed before initiation of firstline therapy, and in 49 (48.5%) it was performed after treatment failure.
Genomic Findings
Tissue HC-based NGS was performed in 82 patients (81.2%) and liquid HC-based NGS was performed in 19 (18.8%). For the tissue assay, biopsy specimens were obtained from the lungs of 40 patients and from metastases of 42 patients. At level 1 analysis, at least one actionable GA was detected in 84 patients (83.2%), including in 73 of the 82 patients with tissue HC-based NGS (89.0%), and in 11 of the 19 patients with liquid HC-based NGS (57.9%). Overall, in 23 patients (22.8%) HC-based NGS detected two actionable GAs, and in six patients (5.9%) it detected three or more actionable GAs. At level 2 analysis, actionable driver GAs were identified in 50 patients (49.5%). The most common genes with mutational or structural change (level 1) involved in the 121 GAs detected in 101 patients were KRAS (18.2%), EGFR (16.5%), RET (7.4%), serine/threonine kinase 11 gene (STK11) (7.4%), ALK (6.6%), ERBB2 (5.8%), and MET (5.8%). At level 2 analysis (Table 2) , the most common actionable GAs in 101 patients were sensitizing EGFR mutations (15%), RET rearrangements (9%), ALK rearrangements (8%), and MET amplifications and/or exon 14 mutations (6%). The proportion of level 2 actionable GAs detected in patients who underwent HC-based NGS before first-line therapy (n ¼ 52) was 54% and that detected in patients who underwent HC-based NGS after treatment failure 47% (n ¼ 49). Interestingly, in 15 patients (14.9%), HC-based NGS detected a GA in EGFR or ALK after negative results of standard molecular testing. Moreover, four additional cases were identified as EGFR/ALK positive by previous standard methods, whereas different drivers were eventually identified by HC-based NGS. The possible a The results of testing of all patients were found to be negative except in five cases in which they were inconclusive for EGFR mutation and in one case in which they were inconclusive for ALK rearrangement. ALK, anaplastic lymphoma receptor tyrosine kinase gene; HC, hybrid capture; NGS, next-generation sequencing. (25) 13 
Note: Of 43 patients treated with targeted therapy on the basis of the results of HC-based NGS, 37 were harboring NCCN-recommended drivers for lung cancer. The other six were treated on the basis of other genomic alterations: NF1 mutation, a high-volume EGFR amplification, KRAS mutation, an NTRK1 variant of unknown significance other than exon 14-activating MET mutation, and a MET variant of unknown significance. reasons for these findings are discussed in the Discussion section.
HC-Based NGS and Changes in Treatment Decisions
After HC-based NGS, 43 patients (42.6%) received targeted therapies accordingly (see Table 2 ). Of these 43 patients, six were excluded from the decision impact analysis as they elected to undergo HC-based NGS before standard EGFR/ALK testing and their HC-based NGS assays detected EGFR/ALK GAs that could have been identified by standard testing. Thus, the calculated exclusive impact of post-PCR/FISH HC-based NGS testing was 36.6%, representing 37 of 101 patients with drivers that could not have been detected otherwise. In 19% of patients (seven of 37), targeted therapy was administered with a concurrent drug (e.g., erb-b2 receptor tyrosine kinase 2 tyrosine kinase inhibitors (TKIs) with chemotherapy [see Supplementary Table 1] ). Tissue HC-based NGS had an impact rate of 45.1% (37 of 82 patients), and liquid HC-based NGS had an impact rate of 31.6% (six of 19) . In addition to the 43 patients who received targeted therapy, two were prescribed targeted therapy but died before initiation of the treatment and two more died shortly before receiving the HC-based NGS report indicating a possible targeted therapy. Of the 43 patients treated with targeted therapy after HC-based NGS, 56% underwent HC-based NGS before first-line therapy and 44% underwent it after treatment failure.
Twelve patients had EGFR mutations and were treated with EGFR TKIs. Another 13 patients were treated with crizotinib: seven had alterations in the ALK gene, four had exon 14 mutations or amplifications in the MET gene, and two had ROS1 rearrangements. Six patients were treated for RET rearrangements with cabozantinib (n ¼ 5) or alectinib (n ¼ 1). Five patients had ERBB2 mutations and were treated with erb-b2 receptor tyrosine kinase 2 TKIs (trastuzumab, trastuzumab emtansine, or pertuzumab). One patient was treated with vemurafenib because of a V600E mutation in the BRAF gene. Another six patients were treated for GAs that were not considered druggable: a neurofibromin 1 gene (NF1) mutation (treated with everolimus), a high-volume EGFR amplification (Â17, erlotinib), non-exon 14 MET mutation of an activating nature (crizotinib), MET (exon 13, E999K) and NTRK1 (S396L) variants of unknown significance (crizotinib), and a KRAS mutation. The patient with the KRAS mutation was enrolled in the SELECT-1 trial and received selumetinib (or placebo) together with docetaxel. This patient was omitted from the response analysis because the nature of the administered treatment was unknown. A full description of the treated patients and the administered drugs is provided in Supplementary Table 1. Of the 43 patients who were treated with targeted therapy, the 19 with ALK/EGFR alterations had their treatment reimbursed by the National Health Insurance Law. Another 23 patients received targeted treatment under off-label use and paid for it individually, were assisted through donations from pharmaceutical companies, or received reimbursement from private insurance companies. As already mentioned, one patient participated in a clinical trial.
Time to Treatment and HC-Based NGS
Median turnaround time for HC-based NGS, excluding shipment time, was 13 days (range 8-460), and treatment started a median of 8 days after receipt of the report (range 0-364). First-line treatment was started within a median of 44 days from diagnosis (range 32-48) in the group of patients who underwent HC-based NGS before their first-line treatment and within a median of 39 days (range 12-122) in the group that underwent HC-based NGS after first-line treatment. The difference between the two groups was found to be not significant (t test p ¼ 0.202). In the latter group, the median time between initiation of first-line treatment and HC-based NGS was 169 days (range 22-1612).
Response to Targeted Therapy and Treatment Duration
Best response to targeted therapy after HC-based NGS, as measured using the Response Evaluation Criteria in Solid Tumors, is summarized in Table 2 and Figure 1 . Of the 43 patients treated upon receipt of the results of HC-based NGS, 34 were evaluable for tumor response. The overall response rate was 64.7% (62% if excluding patients not previously tested). Five patients (14.7%) experienced a systemic complete response (CR); 17 (50%) experienced a partial response (PR), three of whom achieved a metabolic CR; nine (26.5%) experienced stable disease; and three (8.8%) experienced progressive disease. For 13 patients, tumor response evaluation was also available for previous lines of therapy before targeted treatment (Fig. 2) . In these cases, targeted therapy achieved better disease control than did previous lines (77% versus 54%, respectively). Among the 15 patients in whom HC-based NGS detected a GA in EGFR or ALK after negative results of standard molecular testing, 12 were treated with targeted therapies, and CR or PR was reported in eight (67%). Duration of targeted treatment ranged from 1 to 227 weeks at time of analysis (Fig. 3) . Median survival was not reached at the time of analysis; 21 of 43 patients treated with targeted therapy were still alive, with a mean follow-up from diagnosis of stage IV disease of 18 months (range 1-58 months).
TMB and Response to Immunotherapy
During the study period, 33 patients received immunotherapy (either nivolumab [n ¼ 20] or pembrolizumab [n ¼ 13]), 13 of whom were carrying a KRAS mutation. Disease control rate for the whole group was 32% (eight of 25 patients evaluable for tumor response). Data on tumor mutation burden (TMB) was available for 80 patients on whom tissue HC-based NGS was The results of standard testing of all patients for EGFR/ALK alterations before hybrid capture-based next-generation sequencing were negative. ALK, anaplastic lymphoma receptor tyrosine kinase gene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; MET, Mesenchymal-epithelial transition factor receptor tyrosine kinase gene; NTRK1, neurotrophic tyrosine kinase receptor type 1 gene; RET, ret proto-oncogene; PLD, platinum doublet; PLT, platinum triplet (i.e., platinum doublet with bevacizumab); Peme., pemetrexed; Nivo., Nivolumab; Tra., trastuzumab; Per., pertuzumab; Vin., vinorelbine; Pac., paclitaxel; TDM1, trastuzumab emtansine, NA, not available.
performed. Patients who were identified by HC-based NGS as not carrying any treatment-associated driver (n ¼ 17) (level 1 analysis) had the highest mean TMB (11.8 ± 5 mutations/MB]) and the highest overall response rate to immunotherapy (33%). Among KRAS mutation carriers, the average TMB was 6.7 ± 4, and the immunotherapy objective response rate was 10%. As demonstrated by Rizvi et al., 24 our results also showed that a higher TMB was associated, although not significantly, with improved objective response to immunotherapy, with a mean TMB of 9.6 ± 0.8 in patients with a PR as compared with a mean TMB of 5.8 ± 5 in patients with stable or progressive disease (p ¼ 0.27). Immunotherapy response rates according to driver type and TMB data are listed in Table 3 .
Discussion
The diagnostic landscape in NSCLC is evolving rapidly, with new tumor profiling tests becoming available every year. The importance of performing multiplex genetic testing is already well established, and although it is recommended by the National Comprehensive Cancer Network (NCCN), it has yet to be widely adopted.
Despite its strengths, 25, 26 HC-based NGS has several limitations, and its efficacy as a practical tool in therapeutic decision making is yet to be thoroughly evaluated. Of 43 patients treated with targeted therapy after receipt of HC-based NGS results, 41 had available data on duration of targeted treatment. Each bar represents one patient, and the number of weeks of treatment is stated to the right of the bar. If initial targeted therapy was immediately followed by another targeted therapy addressing the same gene, the duration was measured as a whole for the sum of the durations of the treatment. *Other than exon 14 activating MET mutation. **Nonsensitizing EGFR mutation. ***EGFR high-volume amplification (Â17). ALK, anaplastic lymphoma receptor tyrosine kinase gene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; MET, Mesenchymal-epithelial transition factor receptor tyrosine kinase gene; VUS, variation of unknown sequence; NTRK1, neurotrophic tyrosine kinase receptor type 1 gene; RET, ret proto-oncogene; NF1, neurofibromin 1 gene. (8) BRAF all muts 6.7 ± 5. At present, the technological power of HC-based NGS has surpassed the bioinformatic capabilities required to fully understand the genetic findings. Moreover, many GAs are not clinically applicable in the absence of specific targeted treatments that can block the involved oncogenic pathway. In this study, GAs associated with U.S. Food and Drug Administration-approved therapies were assessed, and although presumably targetable drivers were identified in 83% of patients (in level 1 analysis), only half of those patients were actually treated with targeted therapy. A leading example contributing to the creation of this gap is the KRAS gene, which was the most abundant driver. Another limitation is the difficulty of prioritizing drivers for targeted therapy when multiple drivers are present. However, compared with other molecular diagnostic methods, including amplicon-based NGS, HC-based NGS offers the ability to detect the full spectrum of clinically relevant GAs (point mutations, small insertions and deletions, copy number alterations, and genomic rearrangements/fusions) in a single assay, avoiding the need for FISH or other techniques and thereby saving precious tumor tissue and time. In addition, HC-based NGS permits the capture of large intronic regions in which rearrangements or fusions can be detected, and it offers statistically meaningful representation of gene amplifications and deletions, so that numerous types of cancer genome alterations can be enriched from a single sample. 26 The possibility of identifying and potentially treating previously unknown oncogenic GAs is another advantage of HC-based NGS, as performed in our study. Compared with data from amplicon-based NGS, the data on the impact of HC-based NGS on clinical decisions in lung cancer are limited, and further investigation is warranted. Recently, Takeda et al. prospectively applied amplicon-based NGS panels that cover both mutational hotspots in 22 genes related to lung and colon tumorigenesis, and 72 major variants of ALK, RET, ROS1, and NTRK1 fusion transcripts. 27 Actionable genetic alterations were identified in 40% of the 110 study patients, and 21% received targeted therapy, most of whom (83%) bore an EGFR or ALK driver. Notably, as in the Takeda et al. study, 27 prior standard EGFR and ALK testing was not performed, (or used for comparison), and the real advantage of NGS over standard genomic testing is yet to be evaluated. Other groups have also developed amplicon-based NGS methods, [28] [29] [30] as compared with the more complex and expensive HC-based NGS. Drilon et al. used HC-based NGS to evaluate 31 patients in whom previous testing for alterations in 11 oncogenic genes by non-NGS methods had yielded negative results. 31 Actionable GAs associated with a targeted drug according to NCCN guidelines were identified in eight patients (26%), six of whom eventually received targeted therapy.
This study provides a retrospective view on the clinical use of HC-based NGS technologies for lung cancer diagnosis in the real-life setting. Special emphasis was put on patients with EGFR/ALK-negative results and a clinical presentation suggesting that they might have a genomic driver. HC-based NGS before standard molecular testing was preferred in the case of a limited amount of tissue sample, as was the case for 15% of patients in our study, in which the treating physician used HC-based NGS upfront to prevent tissue exhaustion and the potential need for another biopsy. We also used HC-based NGS of cfDNA for 19 tissue-exhausted patients, alleviating the need for an additional invasive biopsy. 20, 32 In this study, we demonstrated that in addition to standard molecular testing (for EGFR/ALK mutation), HC-based NGS resulted in a changed treatment strategy for 37% of patients (n ¼ 37). In 32 of these 37 cases (86%), the chosen treatment replaced chemotherapy, thus being more effective and less toxic and offering potential for improved quality of life and survival. 7, 10, 12, 33 Although defining clinical benefit from treatment in lung cancer may be challenging, in our study, 65% of the patients treated with targeted therapy achieved an objective CR or PR (62% if patients not previously tested are excluded). This rate is evidence of the high accuracy of HC-based NGS, and it is even more impressive considering that almost half of the treated patients (21 of 43 [48.8%]) received targeted therapy after failure of first-line treatment. As expected, patients with EGFR/ALK mutation had better response rates than did patients with other drivers, with rates of CR or PR of 82% (14 of 17) and 47% (eight of 17), respectively. The use of tissue for HC-based NGS is presumably preferable if available. In our cohort, a higher fraction of tissue biopsies resulted in changed treatment strategies (37 of 82 [45%]) compared with liquid biopsies (six of 19 [32%]), although the difference was not significant.
Our results suggest that broad use of HC-based NGS in lung cancer may provide a key for therapeutic decision making and that negative results by standard molecular tests (e.g., PCR and FISH) should not preclude HC-based NGS testing when the probability of identifying a targetable driver is high (e.g., adenocarcinoma in a young patient with a history of a small amount of or never smoking). However, guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology recommend performing molecular testing based on histologic type, irrespective of clinical characteristics (e.g., smoking history, sex, and race). 34 Our study demonstrated a high rate of false-negative results of standard molecular testing for EGFR and ALK mutations (15% [n ¼ 15], with 12 of those patients (80%) treated with targeted therapy after HC-based NGS).
